In most cases of acute myeloid leukemia (AML) malignant stem cells are considered to be within the CD34 þ CD38À population. The involvement of CD34 þ CD38À cells in leukemogenesis is suggested by the presence of cytogenetically aberrant cells in the stem cell compartment in AML, as demonstrated by PCR and FISH for leukemia specific translocations. Furthermore, transplantation studies using NOD/SCID mice have shown that cells with leukemic engraftment and self renewal potential are exclusively found within the CD34 þ CD38À cell population and not in more differentiated CD34 þ CD38 þ populations. 1 Incomplete eradication of these primitive cells may eventually lead to disease relapse. Multidrug resistance induced by the expression of ATP binding cassette (ABC) transporters may hamper the eradication of these primitive leukemic cells.
ABC transporters represent the largest family of transmembrane proteins involved in the transport of a wide variety of substrates across biological membranes, including phospholipids, ions, peptides, steroids, polysaccharides, amino acids, organic anions, bile acids, drugs and other xenobiotics. Currently, the ABC superfamily consists of 48 members; that can be divided into seven subfamilies based on similarity in protein structure (ABCA, B, C, D, E, F and G). Some of these transporters (ABCB1, ABCC1 and ABCG2) are expressed at high levels on hematopoietic primitive cells. 2 The physiological function of ABC transporters in human stem cell biology is not well understood. A role for ABC transporters in the protection from genetic damage by naturally occurring xenobiotics has been suggested for hematopoietic stem cells. 3 This has recently been substantiated by the observation of increased sensitivity to xenobiotics in normal bone marrow cells in ABCB1 and ABCG2/BCRP knockout mice.
Recently, an increasing number of ABC transporters has been associated with extrusion of xenobiotic compounds and chemotherapeutical agents and thus may be important for stem cell protection. However, the expression pattern of many ABC transporters on hematopoietic CD34 þ CD38À cells is currently unknown. In AML overexpression of ABC transporters involved in drug resistance might represent an important mechanism of drug resistance. 2 We recently demonstrated similar expression and function of ABCG2 in CD34 þ CD38À cells in AML and normal bone marrow but observed significant mitoxantrone extrusion from these cells in the presence of ABCG2 inhibition, suggesting the presence of additional drug transporters in these cells.
We assessed gene expression profiles of normal primitive CD34 þ CD38À and more committed CD34 þ CD38 þ progenitor cells by quantitative real-time RT-PCR using micro fluidic cards, covering all 45 transmembrane ABC transporters. Highly enriched CD34 þ CD38À and CD34 þ CD38 þ cells (purity above 90%) were isolated by FACS sorting either from bone marrow (N ¼ 3) or from G-CSF stimulated peripheral blood collections (N ¼ 8).
GAPDH-normalized levels of ABC transporter gene expression in the CD34 þ CD38À cell fraction are shown in Figure 1a . Out of the 45 ABC transporters the expression of 36 ABC transporters was detectable in CD34 þ CD38À cells. Twenty ABC transporters were detectable in all 11 samples. The lower frequency of detection of the remaining 16 ABC transporters is probably due to the relatively low expression level of these genes which will be reflected in a binary answer of the PCR. 4 In line with this, genes with the highest expression level where detectable in all samples whereas genes with a lower expression showed a lower frequency.
The five ABC transporters with the highest levels of expression were ABCA2, ABCC1, ABCB2, ABCB7, and ABCB1, confirming the relatively high expression of known stem cell transporters ABCB1/MDR1 and ABCC1/MRP1. ABC transporter gene expression levels were not significantly different in G-CSF mobilized CD34 þ CD38À cells compared to CD34 þ CD38À cells from normal bone marrow (data not shown). Except for ABCB5, that was detected in all G-CSF mobilized samples (8/8) but not in normal bone marrow (0/3).
To gain more insight in the biological relevance of ABC transporter expression in CD34 þ CD38À cells, we compared this expression pattern to more committed CD34 þ CD38 þ progenitor cells. In CD34 þ CD38 þ cells 38 ABC transporters
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11 11 11 11 11 11 11 11 11 10 11 11 11 11 11 11 11 2 1111111110 4 8 10 7 2 9 4 7 6 4 8 ABCD4  ABCB3  ABCA7  ABCG1  ABCB10  ABCA5  ABCD3  ABCD1  ABCC4  ABCC5  ABCB8  ABCA3  ABCC13  ABCC10  ABCA1  ABCB6  ABCB9  ABCC6  ABCD2  ABCG2  ABCA13  ABCC2  ABCC8  ABCA9  ABCB4  ABCA10  ABCA6  ABCC3  ABCB5  ABCB11  ABCA8  ABCA12  ABCA4  ABCC11  ABCC12  ABCC7  ABCC9  ABCG4  ABCG5  ABCG8 11 11 11 11 11 11 11 11 11 10 11 11 11 11 11 11 11 2 1111111110 4 8 10 7 were detectable. Strikingly, all ABC transporters detectable in the CD34 þ CD38À fraction showed a lower expression in the CD34 þ CD38 þ fraction (Figure 1b) . In 22 of the 36 ABC transporters this difference was statistically significant. Among these genes are known transporters associated with hematopoietic stem cells including ABCB1 (mean 7.57-fold difference, Po0.001), ABCC1 (mean 2.67-fold difference, P ¼ 0.004) and ABCG2 (mean 1.81-fold difference, P ¼ 0.016). Among the 10 most differentially expressed ABC transporters in the normal CD34 þ CD38À vs CD34 þ CD38 þ fraction 5 members of the ABCA family are listed (ABCA5, ABCA6, ABCA9, ABCA10 and ABCA2). Four of these genes, ABCA5, ABCA6, ABCA9 and ABCA10, representing a phylogenetically distinct subgroup within the ABCA gene subfamily, are arranged in a cluster on chromosome 17q24. Although the substrates and function of these ABCA transporters are largely unknown, recent studies suggest that some of these transporters may function in the transmembrane transport of endogenous lipid substrates, such as phospholipids and essential fatty-acids, substrates involved in the regulation of differentiation of hematopoietic cells. 5 Clearly, further research is warranted to elucidate the role of these ABCA transporters in stem cell biology. The ABC transporter expression profiles of all individual samples are included in the Supplementary Information ( Supplementary  Figures 1 and 2) .
The preferential expression of ABC transporters in normal primitive cells and the possible implications of high expression in drug resistance, prompted us to investigate the expression of these transporters in leukemic CD34 þ CD38À cells. ABC transporter gene expression was assessed in CD34 þ CD38À and CD34 þ CD38 þ cells from 12 untreated AML patients. In one leukemic patient sample, we were only able to sort the CD34 þ CD38 þ fraction due to a very low percentage of CD34 þ CD38À cells. Patient characteristics are shown in Table 1 . Others and we have previously shown that CD34 þ CD38À cells in AML are predominantly of leukemic origin. GAPDH was used as a reference gene since we have earlier demonstrated that this is an appropriate gene for normalization of target gene expression with similar expression levels in both normal and leukemic CD34 þ CD38À and CD34 þ CD38 þ cells. 6 In the leukemic CD34 þ CD38À cell fraction, 40 out of 45 ABC transporters were detectable (Figure 2a ). All genes that were detectable in normal CD34 þ CD38À progenitor cells were also detectable in leukemic CD34 þ CD38À cells, with the exception of ABCA8 that was found only in one of the 11 normal CD34 þ CD38À samples. The level of expression of 31 out of 35 ABC transporters was comparable in both normal and leukemic CD34 þ CD38À cells. A statistically significant lower expression in the CD34 þ CD38À cells in AML compared to the same fraction in normal cells was found for four ABC transporters, ABCA3 (P ¼ 0.003), ABCA5 (P ¼ 0.003), ABCB1 (P ¼ 0.001) and ABCC1 (P ¼ 0.011). A significant difference in frequency of expression between normal and leukemic CD34 þ CD38À cells was found for ABCA13 (10/11 vs 3/11, respectively; Po0.05) and ABCB5 (8/11 vs 1/11, respectively, Po0.05). Finally, in the leukemic CD34 þ CD38À cell population five ABC transporters were detectable that were not found in their normal counterparts (ABCA4, ABCC7, ABCC9, ABCC11 and ABCG4). The frequency of detectable expression of these transporters, however, was very low (ABCA4; 2/11, ABCC7; 1/11, ABCC9; 4/11, ABCC11; 2/11 and ABCG4; 1/11) and may reflect a binary answer of the PCR in case of borderline expression levels, rather than indicating leukemia-specific expression of these genes. The ABC transporter expression results of the individual AML patients are included in the Supplementary Information ( Supplementary  Figures 3 and 4) .
Similar to the expression pattern in normal bone marrow, statistically significant higher expression in the CD34 þ CD38À cells compared to the CD34 þ CD38 þ cells was found for 27/ 40 ABC transporters in AML (Figure 2b) .
Currently, 13 ABC transporters are thought to be involved in transport of cytostatic drugs, and may, therefore, be involved in multidrug resistance. In addition to the expected transporters, ABCB1, ABCC1 and ABCG2, all other ABC transporters involved in drug transport were expressed in CD34 þ CD38À cells in AML at varying frequencies. Six ABC drug transporters were expressed in CD34 þ CD38À cells of all AML patients and statistically significant differential expression in CD34 þ CD38À cells compared to CD34 þ CD38 þ cells was found in 8/13 ABC drug transporters. Percentages of blasts and CD34+ cells are based on morphology and immunophenoptypic staining, respectively. CD34+CD38À cells were defined as the cells with CD38-PE fluorescence within the first decade of emission. The CD34+CD38+ cells were sorted from a gate positioning in the bulk of CD34+ cells separated by a decade from CD34+CD38À cells. The percentages of CD34+CD38À and CD34+CD38+ cells are the percentages of cells within the gates used in the sorting procedure relative to the total amount of cells.
Letters to the Editor
The current study is the first reporting the ABC transporter gene expression profile of human hematopoietic primitive cells using real-time RT-PCR but differential expression of ABC transporters in (non-human) hematopoietic stem cells has been described earlier for some transporters. Ramalho-Santos et al. 1.E-02
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hematopoietic stem cells in comparison to their differentiated counterparts using microarray expression profiling. They showed that eight ABC transporters were differentially expressed. All these genes, except ABCB8, showed significantly higher expression in normal CD34 þ CD38À cells in comparison to committed progenitor cells in our study. Similarly, gene expression profiling in fetal Sca þ AA4.1 þ Kit þ LinÀ liver hematopoietic cells vs stem cell-depleted AA4.1À cells 8 identified 14 differentially expressed ABC transporters, all of which, when included, have higher expression in human CD34 þ CD38À cells in our study, except ABCG3 which has no human ortholog. These comparisons indicate that the reported expression profiles of ABC transporters in hematopoietic (stem) cell populations show high concordance with the results from our study. In addition to the expected differentially expressed ABC transporters, we identified a large number of ABC transporter genes, previously unknown to be expressed in CD34 þ CD38À and CD34 þ CD38 þ cells, which displayed higher expression in hematopoietic primitive cells compared to more committed progenitor cells. The higher sensitivity of realtime RT-PCR in comparison to cDNA and oligonucleotide arrays, especially in low copy genes, may explain the identification of these genes in the current study.
We demonstrate expression of all 13 ABC transporter members currently associated with drug resistance. The conserved expression of these drug resistance associated transporters after malignant transformation in AML could greatly impede sensitivity of the leukemic CD34 þ CD38À cells to chemotherapeutical eradication, if mRNA expression levels reflect protein levels and function. If so, these data suggest that many members of the ABC transporter family may be involved in drug efflux mediated resistance of leukemic CD34 þ CD38À cells. Modulation of multiple transporters might be required to increase drug accumulation and induce chemotherapeutical eradication of primitive leukemic cells in AML.
This has to be taken into account when interpreting the largely poor results of ABCB1 modulation using the potent inhibitor PSC833 on long-term disease outcome in clinical trials. It is important to stress that one of the main rationales for ABCB1 targeting is its prognostic value for remission induction in AML. Based on the results of the current study, it is conceivable that ABCB1 may be a prognostic marker for AML cases that consist predominantly of immature CD34 þ cells that co-express a high number of ABC transporter molecules with putative involvement in drug extrusion and chemotherapy resistance.
Additionally, the similar patterns of ABC transporter expression in normal and leukemic hematopoietic CD34 þ CD38À cells predict that modulation of these transporters in AML as a therapeutic strategy to target leukemic primitive cells will target residual normal hematopoietic primitive cells as well and is therefore likely to encounter increased bone marrow toxicity.
Finally, the identification of previously unrecognized ABC transporters in leukemic primitive cells offers the basis for future studies investigating the functional role of these ABC transporters in leukemia resistance and their usefulness as therapeutically targets to eradicate this crucial cell population in AML.
